scholarly journals Multifokaler/multizentrischer Brustkrebs: Klinisches/epidemiologisches Profil und immunhistochemische Muster unter den Brennpunkten: Querschnittsstudie

Author(s):  
Kamila Bezerra Fernandes Diocesano ◽  
Aurélio Antonio Ribeiro Costa ◽  
Glauber Moreira Leitão

Multifokaler/multizentrischer Brustkrebs (MF/MC) ist eine Krankheit, die viele Paradigmen in der aktuellen Praxis von Brustkrebs umfasst. Um Morbidität und Sterblichkeit zu bekämpfen, ist die beste Option eine rationale therapeutische Strategie, die mit einem klaren biologischen Verständnis von Multizentrizität und Multifokalität beginnen sollte, da dies bekannt ist, kann die richtige Behandlung befolgt werden. Unser Ziel war es, das Profil von Patienten mit multifokalem und multizentrischem Brustkrebs zu definieren und zu bewerten, ob es Meinungsverschiedenheiten zwischen Tumorherims in Bezug auf Hormonrezeptor und Her-2 gibt. Wir analysierten retrospektiv 89 Patienten mit multifokalem und multizentrischem invasivem Brustkrebs in zwei tertiären Einrichtungen im Nordosten Brasiliens, bewerteten Hormonrezeptoren, Her-2 und ki67 in jedem Tumorfokus von 25 dieser Patienten, wobei wir die Meinungsverschiedenheiten zwischen ihnen und Typ und histologische minologische Rand- und Bewertungsgrad, Lymphknotenmetastasierung und Entfernung und Alter hervorhoben. Von diesen Patienten stellten 9 % eine Heterogenität zwischen Tumor-Brennpunkten dar. Der Anteil der Metastasen im axillären Lymphknoten betrug 42% und nur 10% bei entfernter Metastasierung. 45 % der Frauen in der Studie hatten histologische Grade II oder III. Wir fanden eine Prävalenz von 40,5% der negativen Her-2 und 45% der positiven Östrogen-Rezeptor. Es gab keinen statistisch signifikanten Unterschied zwischen multifokalen und multizentraten Krebs. Wir kommen zu dem Schluss, dass MF/MC-Brustkrebs eine Heterogenität zwischen Tumorherims in Bezug auf biologische Parameter zeigt, was eine entscheidende Rolle bei der Entscheidungsfindung über die Behandlung und damit über Tumorrezidiv, Prognose und entfernte Metastasierung spielt.

2021 ◽  
Vol 11 (5) ◽  
pp. 392-400
Author(s):  
Fajar Lamhot Gultom ◽  
Marliana Nurprilinda ◽  
Ryani Nur Cahyaning Hutami

Immunohistochemistry examination (IHC) is one of the additional tests to diagnose and determine breast cancer subtype. IHC examination is a method to check intracellular protein using a monoclonal and polyclonal antibody to detect the antigen in tissue. IHC examination determined by hormone receptor markers (ER and PR), HER-2/Neu expression, and apoptotic and proliferation markers (Ki-67 and p53) can be used to determine therapy and prognosis. This study aims to determine the hormonal status of breast cancer patient at Siloam Semanggi Hospital in 2018, in the form of age, gender, pathology diagnose, and the result of IHC (ER, PR, HER2, and Ki-67). This study is a retrospective descriptive study using pathological anatomy laboratory results of breast cancer in MRCCC Siloam Semanggi Hospital and 208 patients following inclusion and exclusion criteria. The result obtained is that the age group with the highest frequency is 50-59 years, with 34.1%. The highest frequency by gender is a woman with 99.5%. Carcinoma mammae NST with grade II and III was found in 38.0% of patients. The hormonal receptor with ER and PR positive was found in 51.0% of patients. HER2 expression negative was found in 56.7% of patients. High proliferation Ki-67 was found in 82.7% of patients. Luminal B with HER2 negative subtype was found in 32.2% of patients. Patients in 50-59 years with Luminal B with HER2 negative subtype was found in 26 patients. Patients in carcinoma mammae NST with grade II with Luminal B with HER2 negative subtype was found in 27 patients. Keywords: Breast cancer, pathologic anatomy, immunohistochemistry, breast cancer subtype


2019 ◽  
Vol 88 (1) ◽  
pp. 43-47 ◽  
Author(s):  
Lígia Fernandes Gundim ◽  
Taís Meziara Wilson ◽  
Nicolle Pereira Soares ◽  
Igor de Paula Castro ◽  
Mariana Ribeiro Castro ◽  
...  

Due to the high occurrence of mammary neoplasms in cats, the search for prognostic factors has recently intensified. Human epidermal growth factor receptor type 2 (Her-2) is prominent among the immunohistochemical markers used for prognosis. The aim of this study was to evaluate the expression of Her-2 in mammary lesions in queens and relate the expression to the type and histological grade of mammary carcinomas. Thirty-eight cases were selected from 2006 to 2016 and were classified and histologically graded. Her-2 expression was determined through immunohistochemistry, using a semi-quantitative analysis of the slides according to the scores recommended in the Dako HercepTest. Chi-square test was used to evaluate the relationship between Her-2 expression and mammary lesion type and the type and histological grade of carcinoma (P < 0.05). The mean age was 8.5 years and young cats were affected only by benign hyperplasias and neoplasms. Undefined cats were more affected (84.37%), followed by Siamese (9.37%) and Persian (6.25%) cats. Regarding the histological classification, 18.42% of the mammary lesions were classified as hyperplasia, 18.42% as adenoma, and 63.16% as carcinoma. The most common type of carcinoma was tubulopapillary carcinoma (66.7%), followed by solid carcinoma (25%) and cribriform carcinoma (8.33%). Her-2 overexpression was observed in four samples (16.7%) of tubulopapillary carcinoma, two grade I carcinomas and two grade II carcinomas, but no relationship was observed between Her-2 expression and type of mammary lesion (P = 0.3127), carcinoma type (0.3446), or histological grade (0.6485). In conclusion, Her-2 overexpression is unrelated to histological grade and type.


2018 ◽  
Vol 7 (1) ◽  
pp. 6-11
Author(s):  
Rameez Hasan ◽  
Deepti Bhatt ◽  
Shahbaz Khan ◽  
Vasiuddin Khan ◽  
Amit Kumar Verma ◽  
...  

BACKGROUND: Human epidermal growth factor receptor 2 (HER-2) is an oncogenic gene and a well-established therapeutic target in several cancers including breast and ovary. AIM: The present study aimed to compare HER-2 expression status with histological grades as well as Clinicopathological parameters including age, bleeding per rectum, pain/burning sensation in defecation and exercise. METHODS: Her-2 status was assessed by immunohistochemistry (IHC). RESULTS: Results of the study shows that 40.96% patients were Her-2 positive for expression and a statistically significant difference (p-value = 0.004) was observed in histological grades where most of the cases were of grade II. We also observed a significant difference in histological grades with gender (p-value = 0.04), as well as in both the age groups ≤ 55 years and > 55 years (p-value = < 0.0001). Patients with the bleeding rectum and pain/burning sensation in defecation had grade II/III tumours (93.4%, 88.7%) respectively. A significant association was observed between bleeding per rectum and pain/burning sensation in defecation. About 95% of patients with pain/burning sensation in defecation had bleeding per rectum. CONCLUSION: To conclude, Her-2 can be a potential prognostic marker in CRC. The role of age, tumour grade and bleeding per rectum/burning sensation in defecation are of significant worth. Thus, CRC cases of high grades can be screened for HER-2/neu positivity so that they can be subjected to mAb-based individualised therapy.


2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11003-11003 ◽  
Author(s):  
H. S. Han ◽  
P. Doliny ◽  
M. Blaya ◽  
S. Gluck ◽  
J. Slingerland ◽  
...  

11003 Background: Docetaxel, cisplatin, and trastuzumab given every 21 days in Her 2-postitive breast cancer demonstrates a pathologic complete response (pCR) rate of 23%. Decreasing the interval between doses of chemotherapy has lead to improvement in survival in the adjuvant setting. In one study dose dense chemotherapy improved response only in patients whose tumors overexpressed her-2. We conducted a phase II trial to evaluate the efficacy and safety of neoadjuvant dose-dense TCH for HER 2-positive breast cancer. Methods: Patients with T2–4 N0–3 M0 HER-2 positive (by FISH) breast cancers were eligible. Neoadjuvant therapy consisted of carboplatinum (AUC 6) Day 1,15,29,43, docetaxel (75mg/m2) Day 1,15,29, 43 and weekly trastuzumab for 10 weeks 4mg/kg Day 1 then 2mg/kg Day 8,15,22,29,36,43,50,57,64, Pegfilgastrim Day 2,16,30,44. The primary end point was the rate of pCR. Results: Twenty patients are evaluable for response. The median age was 51.5 years (range 29–73). Mean tumor size was 5.6 cm. Patients had stage IIA (30%), IIB (15%), IIIA (45%), IIIB (5%), and IIIC (5%). Estrogen receptors were positive in 36% of tumors. No grade 4 or 5 toxicity occurred. The most frequent toxicity was hand-foot syndrome (Grade I 15%, Grade II 10%, Grade III 15%). Neutropenia occurred in 5 patients (Grade II 10%, Grade III 15%) There were no episodes of febrile neutropenia or hospitalizations. Grade I cardiotoxicity was seen in 30%. The rate of pCR was 40% in the breast and 35% in both breast and axilla. 16/20 patients (80%) had pathologically negative lymph nodes. Conclusions: Changing the scheduling of TCH from every 21 days to every 14 days improves the pCR rate from 23 to 40%. The regimen was well tolerated. No significant financial relationships to disclose.


2004 ◽  
Vol 171 (4S) ◽  
pp. 114-114
Author(s):  
Akira Yokomizo ◽  
Hirofumi Koga ◽  
Koji Okumura ◽  
Tatsuo Konomoto ◽  
Taiji Tsukamoto ◽  
...  

2018 ◽  
Vol 66 (3) ◽  
pp. 145-155 ◽  
Author(s):  
Rolf-Dieter Stieglitz ◽  
Harald J. Freyberger ◽  
Wolfgang Hiller

Zusammenfassung. In der klinischen Praxis gewinnen evidenzbasierte Behandlungsleitlinien zunehmend an Bedeutung. Innerhalb dieser finden sich jedoch nur unbefriedigende Informationen zur Diagnostik, speziell im Hinblick auf eine therapie-begleitende Diagnostik. Der Erfolg einer Therapie, ob Psycho- und/oder Pharmakotherapie, hängt jedoch von der Verzahnung von Therapie und Diagnostik ab, um z.B. den Therapieverlauf und -erfolg zu bewerten und bei Bedarf die therapeutische Strategie zu ändern. Der Ansatz des Evidence-Based Assessment (EBA) bietet hier ein hilfreiches Rahmenmodell und konkrete Vorschläge sowie Kriterien zur Realisierung dieser Verzahnung. Im Beitrag soll EBA vorgestellt sowie anhand ausgewählter Störungsgruppen illustriert werden.


2008 ◽  
Author(s):  
Ming-Chuan Hsu ◽  
Chee-Yin Chai ◽  
Ming-Feng Hou ◽  
Hui-Chiu Chang ◽  
Wan-Tzu Chen ◽  
...  

2009 ◽  
Vol 69 (03) ◽  
Author(s):  
V Porto ◽  
I Mutz-Dehbalaie ◽  
J Rössler ◽  
A Wiedemair ◽  
A Sapinsky ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document